ANTI-INTEGRIN ALPHAVBETA3 ANTIBODY CLONE LM609 AZIDE FREE

General description

The integrin family of cell adhesion receptors consists of at least 16 membrane-associated heterodimers, composed of an alpha and beta subunit that associate in a non-covalent manner. The structure and functional diversity of the integrin family are based upon the pairing abilities of the individual alpha and beta subunits. Key to these molecular interactions between the integrin receptors and their respective ligands is the recognition of the Arg-Gly-Asp (RGD) sequence, known to be present in the extracellular matrix components fibronectin, vitronectin, collagen, fibrinogen, and von Willebrand factor (Cheresh, 1991). The involvement of integrins in vascular proliferation, adhesion, and wound repair has been well documented. The adhesion receptor, integrin alphaVbeta3, appears to be selectively expressed on growing blood vessels and has been identified as a marker of angiogenic vascular tissue (Brooks, 1994). Due to its involvement in angiogenesis, integrin alphaVbeta3 is one of the most intensely studied of the integrin receptors.

Specificity

Reacts with the vitronectin receptor alphaVbeta3 complex, an RGD-directed adhesion receptor. LM609 has been demonstrated to block adhesion of a human melanoma cell line (M21) to vitronectin, fibrinogen and von Willebrand factor, as well as to a synthetic RGD containing peptide (Cheresh, 1987). In chick chorioallentoic membranes, LM609 was shown to block angiogenesis induced by bFGF and TNFalpha but had no effect on pre-existing vessels (Brooks, 1994). While LM609 does block cell attachment to RGD containing ligands, it does not interact directly with the RGD binding site. Instead, LM609 appears to be an allosteric inhibitor of integrin alphaVbeta3, which binds to a conformational epitope resulting from the post-translational association of the alphaV and beta3 subunits.

Immunogen

Purified adhesion receptor from the human melanoma cell line M21 (Cheresh, 1987).

Application

Flow Cytometry: 1-3 μg LM609 per 0.5 x 10e6 cells in 100μL (Smith, 1996).

Immunoprecipitation: specifically immunoprecipitates the integrin alphaVbeta3 complex which, when resolved by SDS-PAGE under reducing conditions, results in an approximately 130 kDa band corresponding to the alphaV subunit and a 105 kDa band corresponding to the beta3 subunit (Cheresh, 1987).

Immunofluorescence: 5-10 μg/mL for staining of bFGF-treated 6 mm cryosections of chick chorioallantoic membrane fixed with acetone (Brooks, 1994). LM609 is also effective on 4% paraformaldehyde fixed, frozen tissues and cells. However it is not effective for immunohistochemical staining of paraffin-embedded tissue sections.

Inhibits adhesion of cells to vitronectin coated surfaces at 10-25 μg/mL.

Optimal working dilutions and protocols must be determined by end user.

Research Category
Cell Structure

Research Sub Category
Integrins

This Anti-Integrin αVβ3 Antibody, clone LM609, Azide Free is validated for use in FC, IH, IP, FUNC for the detection of Integrin αVβ3.

Target description

Molecular Weight of Integrin αV: 125-135 kDa

Physical form

Format: Purified

Protein A Purified mouse immunoglobulin in 20 mM sodium phosphate, 250 mM NaCl, pH. 7.6, with no preservatives.

Protein A purified

Storage and Stability

Maintain at 2–8°C in undiluted aliquots for up to 6 months.

Analysis Note

Control
Positive Control: Human myeloma cell lines M21 and MoαV (Chen, 1995).
Negative Control: Mo cells (this cell line was derived from M21 but does not express integrin αV

Chen, 1995)

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.